Osteogenic Compound Compositions for Bone Formation and Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis focus on inhibiting bone resorption rather than promoting bone formation, leading to potential failure of bone repair and increased risk of fractures due to imbalance in osteoblast and osteoclast activities.
Innovation Solution
Pharmaceutical compositions containing osteogenic compounds, such as phenanthrenes or their derivatives, are administered to stimulate osteoblast differentiation, activity, and survival, enhancing calcium deposition, osteogenic protein expression, and Wnt/β-catenin signaling pathway activity to promote bone formation and inhibit osteoclast resorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of substance
If anti-resorptive agents are used to inhibit osteoclastic activity and reduce bone loss, then bone resorption is reduced, but bone remodeling fails leading to microcracks and bone necrosis
Solution Approach 1:
Instead of continuing to suppress osteoclastic activity with anti-resorptive agents, the patent inverts the approach by using osteogenic agents to stimulate osteoblastic bone formation. This shifts the therapeutic strategy from inhibition to activation, promoting new bone formation to replace old bone rather than merely preventing bone loss.
Solution Approach 2:
The patent changes the therapeutic parameter from inhibiting osteoclasts to activating osteoblasts. By using osteogenic agents that stimulate osteoblastic differentiation and activity, the treatment paradigm shifts from reducing bone resorption to enhancing bone formation, thereby restoring normal bone remodeling dynamics.
2Loss of substance
If estrogen is used to treat osteoporosis in postmenopausal women, then bone mass is maintained, but risk of breast and uterine cancer increases
Solution Approach 1:
The patent replaces long-term estrogen therapy with alternative osteogenic agents that achieve the same bone-protective effect without the harmful side effects. These osteogenic agents act as substitutes that provide the necessary therapeutic benefit (maintaining bone mass) while avoiding the dangerous long-term consequences (cancer risk) of estrogen therapy.
Solution Approach 2:
The patent introduces osteogenic agents as intermediary substances that mediate between the need for bone mass maintenance and the avoidance of cancer risk. These agents serve as a middle ground, providing osteoprotective effects through osteoblastic stimulation without the carcinogenic effects of estrogen, thus acting as a safer intermediary therapeutic option.
3Duration of action of stationary object
If prolonged treatment with anti-resorptives is used to suppress bone remodeling, then bone loss is reduced, but failure of repair and bone necrosis occur
Solution Approach 1:
The patent promotes a treatment approach that enables periodic bone remodeling rather than continuous suppression. By stimulating osteoblastic activity to form new bone, the treatment allows the bone remodeling cycle to proceed naturally with periods of formation and resorption, preventing the continuous suppression that leads to repair failure and necrosis.
Data Source
AI summary
Compositions and methods for reducing, or inhibiting bone loss in a subject in need thereof have been developed. Pharmaceutical compositions including one or more osteogenic compounds, or functional derivatives thereof, in an effective amount to reduce, or inhibit bone loss, or promote bone formation, preferably via stimulation of osteoblast differentiation, are provided. The compositions are particularly suited for treating bone loss associated with osteoporosis. Methods for treating, or preventing bone loss using the composition, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents, or procedures, are described.